Arkolith/Insider Trading/CRNX/Form 4

Pizzuti Dana

Chief Med and Dev OfficerCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Dec 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$225K
Net Open-Market Flow
-$225K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 1, 2025Sell(S)5K$45.02$225K67K
Dec 1, 2025Option exercise(M)5K$16.89$84K72K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 1, 2025Option exercise(M)5K—$069K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-055054) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML